Plain-English translation of NCT07693140 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing low-dose whole-brain radiotherapy as a potential treatment for Alzheimer's disease and related dementias that involve inflammation in the brain. The treatment delivers very small radiation doses over several sessions — much smaller than radiation used to treat cancer. Researchers want to see if this approach is safe and whether it might help slow cognitive decline in patients with mild to moderate memory problems.
Inflammation in the brain may play a role in Alzheimer's disease and some types of dementia, but current treatments don't directly address this inflammation. This trial explores whether the treatment might reduce brain inflammation and slow the progression of memory loss in a way that existing medications cannot.
You likely qualify if…
You likely don't qualify if…
You would receive an initial course of 10 radiation treatments over a few weeks. Then, starting two months later, you would return to the clinic once a month for 12 months to receive additional maintenance treatments — 10 small radiation doses each month. Throughout the trial, you'll have regular clinic visits to monitor how you're doing, with blood tests and brain scans to track any changes. Your caregiver would need to accompany you to most visits.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
United States
Phase
Safety & dosing / Early efficacy
Sponsor
Evan Thomas
Enrollment target
~50 participants
Started
July 2026
Primary completion
May 2029
Age range
50 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Julia Pierson, BS
Renaissance Institute of Precision Oncology and Radiosurgery
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.